Type-specific human papillomavirus prevalence in women referred for colposcopy in Tehran
-
Rahim Soleimani-Jelodar
,
Arash Arashkia
,
Zabihollah Shoja
,
Kimia Sharifian
,
Setareh Akhavan
,
Fariba Yarandi
,
Somayeh Jalilvand
Abstract
Background and Objectives: Although several studies have been achieved on the frequency of the HPV types among women with cervical cancer in Iran, HPV-positive samples were in some cases directed to specific-primer genotyping of HPV 16 and 18. Therefore, the other HPV types are underestimated. Several studies have also reported a greater prevalence of HPV 16 in cervical cancer in Iran than in the world. To clarify these subjects, the distribution of HPV types in women referred for colposcopy in Tehran was investigated.
Materials and Methods: In this cross-sectional study, a total of 148 cervical samples from women with normal, atypical squamous cells of undetermined significance, cervical intraepithelial neoplasia I-III, and invasive cervical cancer histopathology were included. HPV was detected by PCR assay and all HPV-positive specimens were subjected to direct nucleotide sequencing.
Results: Our results demonstrated that the total prevalence of HPV was 92.5%. The five most common HPV types were HPV 16 (49.3%), 18 (14.8%), 6 (7.4%), 31 (4.1%), and 11 (2.7%). About the histopathological stage, HPV 16 and 18 were dominant in all studied groups. In cervical cancer, HPV 16 and 18 were detected in 60% and 20% of cases, respectively.
Conclusion: HPV 16 and 18 were the most common in cervical cancer in Iran.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 Suppl 5(0 5): F24-F33.
3. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384: 260-265.
4. Dos Santos LM, de Souza JD, Mbakwa HA, Nobre AFS, Vieira RC, Ferrari SF, et al. High prevalence of sexual infection by human papillomavirus and Chlamydia trachomatis in sexually-active women from a large city in the Amazon region of Brazil. PLoS One 2022; 17(7): e0270874.
5. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25 Suppl 1(Suppl Suppl 1): 2-23.
6. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 Suppl 5: F55-F70.
7. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10: 321-322.
8. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El GF. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
9. Munoz N, Bosch FX, de SS, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
10. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3: S3/1-10.
11. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419-1424.
12. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772.
13. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85: 719-726.
14. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; Suppl 5(0 5): F123-F138.
15. Zhai L, Tumban E. Gardasil-9. A global survey of projected efficacy. Antiviral Res 2016; 130: 101-109.
16. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel) 2020; 8: 391.
17. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2021.
18. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-935.
19. Salavatiha Z, Farahmand M, Shoja Z, Jalilvand S. A meta-analysis of human papillomavirus prevalence and types among Iranian women with normal cervical cytology, premalignant lesions, and cervical cancer. J Med Virol 2021; 93: 4647-4658.
20. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. J Med Virol 2015; 87: 287-295.
21. Esmaeili M, Bonyadi M, Dastranj A, Alizadeh M, Melli MS, Shobeiri MJ. HPV typing in women with cervical precancerous and cancerous lesions in northwestern Iran. Gynecol Obstet Invest 2008; 66: 68-72.
22. Heydari N, Oskouee MA, Vaezi T, Shoja Z, Esmaeili HA, Hamkar R, et al. Shahmahmoodi S, Jalilvand S. Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. J Med Virol 2018; 90: 172-176.
23. Mortazavi SH, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev 2002; 3: 69-72.
24. Shahsiah R, Khademalhosseini M, Mehrdad N, Ramezani F, Nadji SA. Human papillomavirus genotypes in Iranian patients with cervical cancer. Pathol Res Pract 2011; 207: 754-757.
25. Lucas-Roxburgh R, Benschop J, Lockett B, van den Heever U, Williams R, Howe L. The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand population. PLoS One 2017; 12(10): e0186424.
26. Huang Y, Wu X, Lin Y, Li W, Liu J, Song B. Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development. Oncol Lett 2020; 20: 1915-1921.
27. de Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira ÉC, Pereira MW, et al. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res 2016; 6: 1371-1383.
28. Mzarico E, Gómez-Roig MD, Guirado L, Lorente N, Gonzalez-Bosquet E. Relationship between smoking, HPV infection, and risk of Cervical cancer. Eur J Gynaecol Oncol 2015; 36: 677-680.
29. Sharifian K, Shoja Z, Jalilvand S. The interplay between human papillomavirus and vaginal microbiota in cervical cancer development. Virol J 2023; 20: 73.
30. Naldini G, Grisci C, Chiavarini M, Fabiani R. Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis. Int J Public Health 2019; 64: 943-955.
31. Chen H, Luo L, Wen Y, He B, Ling H, Shui J, et al. Chlamydia trachomatis and human papillomavirus infection in women From Southern Hunan Province in China. A large observational study. Front Microbiol 2020; 11: 827.
32. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect 2019; 25: 35-47.
33. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-935.
34. Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2389-2400.
35. Giorgi Rossi P, Sideri M, Carozzi FM, Vocaturo A, Buonaguro FM, Tornesello ML, et al. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer 2012; 7: 26.
36. Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C, Unger ER, et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS One 2012; 7(3): e34044.
37. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-1164.
38. Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121: 32-42.
2. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 Suppl 5(0 5): F24-F33.
3. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384: 260-265.
4. Dos Santos LM, de Souza JD, Mbakwa HA, Nobre AFS, Vieira RC, Ferrari SF, et al. High prevalence of sexual infection by human papillomavirus and Chlamydia trachomatis in sexually-active women from a large city in the Amazon region of Brazil. PLoS One 2022; 17(7): e0270874.
5. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25 Suppl 1(Suppl Suppl 1): 2-23.
6. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 Suppl 5: F55-F70.
7. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10: 321-322.
8. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El GF. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
9. Munoz N, Bosch FX, de SS, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
10. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 Suppl 3: S3/1-10.
11. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419-1424.
12. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772.
13. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85: 719-726.
14. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; Suppl 5(0 5): F123-F138.
15. Zhai L, Tumban E. Gardasil-9. A global survey of projected efficacy. Antiviral Res 2016; 130: 101-109.
16. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel) 2020; 8: 391.
17. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2021.
18. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-935.
19. Salavatiha Z, Farahmand M, Shoja Z, Jalilvand S. A meta-analysis of human papillomavirus prevalence and types among Iranian women with normal cervical cytology, premalignant lesions, and cervical cancer. J Med Virol 2021; 93: 4647-4658.
20. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. J Med Virol 2015; 87: 287-295.
21. Esmaeili M, Bonyadi M, Dastranj A, Alizadeh M, Melli MS, Shobeiri MJ. HPV typing in women with cervical precancerous and cancerous lesions in northwestern Iran. Gynecol Obstet Invest 2008; 66: 68-72.
22. Heydari N, Oskouee MA, Vaezi T, Shoja Z, Esmaeili HA, Hamkar R, et al. Shahmahmoodi S, Jalilvand S. Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. J Med Virol 2018; 90: 172-176.
23. Mortazavi SH, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev 2002; 3: 69-72.
24. Shahsiah R, Khademalhosseini M, Mehrdad N, Ramezani F, Nadji SA. Human papillomavirus genotypes in Iranian patients with cervical cancer. Pathol Res Pract 2011; 207: 754-757.
25. Lucas-Roxburgh R, Benschop J, Lockett B, van den Heever U, Williams R, Howe L. The prevalence of human papillomavirus in oropharyngeal cancer in a New Zealand population. PLoS One 2017; 12(10): e0186424.
26. Huang Y, Wu X, Lin Y, Li W, Liu J, Song B. Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development. Oncol Lett 2020; 20: 1915-1921.
27. de Abreu AL, Malaguti N, Souza RP, Uchimura NS, Ferreira ÉC, Pereira MW, et al. Association of human papillomavirus, Neisseria gonorrhoeae and Chlamydia trachomatis co-infections on the risk of high-grade squamous intraepithelial cervical lesion. Am J Cancer Res 2016; 6: 1371-1383.
28. Mzarico E, Gómez-Roig MD, Guirado L, Lorente N, Gonzalez-Bosquet E. Relationship between smoking, HPV infection, and risk of Cervical cancer. Eur J Gynaecol Oncol 2015; 36: 677-680.
29. Sharifian K, Shoja Z, Jalilvand S. The interplay between human papillomavirus and vaginal microbiota in cervical cancer development. Virol J 2023; 20: 73.
30. Naldini G, Grisci C, Chiavarini M, Fabiani R. Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis. Int J Public Health 2019; 64: 943-955.
31. Chen H, Luo L, Wen Y, He B, Ling H, Shui J, et al. Chlamydia trachomatis and human papillomavirus infection in women From Southern Hunan Province in China. A large observational study. Front Microbiol 2020; 11: 827.
32. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect 2019; 25: 35-47.
33. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-935.
34. Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2389-2400.
35. Giorgi Rossi P, Sideri M, Carozzi FM, Vocaturo A, Buonaguro FM, Tornesello ML, et al. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer 2012; 7: 26.
36. Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C, Unger ER, et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS One 2012; 7(3): e34044.
37. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-1164.
38. Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121: 32-42.
| Files | ||
| Issue | Vol 16 No 3 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v16i3.15799 | |
| Keywords | ||
| Human papillomavirus; Uterine cervical neoplasms; Cervical intraepithelial neoplasia; Atypical squamous cells of the cervix; Human papilloma virus vaccines | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Soleimani-Jelodar R, Arashkia A, Shoja Z, Sharifian K, Akhavan S, Yarandi F, Jalilvand S. Type-specific human papillomavirus prevalence in women referred for colposcopy in Tehran. Iran J Microbiol. 2024;16(3):421-427.
